These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27544029)

  • 1. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway.
    Li R; Chen LZ; Zhao W; Zhao SP; Huang XS
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1173-8. PubMed ID: 27544029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metformin reduces plasma triglycerides in ob/ob obese mice via inhibiting the hepatic apoA5 expression].
    Huang X; Li R; Chen L; Dai W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 42(12):1389-1394. PubMed ID: 29317579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway.
    Zhao SP; Li R; Dai W; Yu BL; Chen LZ; Huang XS
    PLoS One; 2017; 12(9):e0184949. PubMed ID: 28934253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity.
    Huang XS; Zhao SP; Hu M; Bai L; Zhang Q; Zhao W
    Atherosclerosis; 2010 Jun; 210(2):563-8. PubMed ID: 20047745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.
    Lin MJ; Dai W; Scott MJ; Li R; Zhang YQ; Yang Y; Chen LZ; Huang XS
    Oncotarget; 2017 Dec; 8(65):108802-108809. PubMed ID: 29312569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
    Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
    Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
    Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Statin reduced triglyceride level via activating peroxisome proliferator activated receptor α and upregulating apolipoprotein A5 in hypertriglyceridemic rats].
    HUANG XS; ZHAO SP; BAI L; ZHANG Q; HU M; ZHAO W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep; 38(9):809-13. PubMed ID: 21092650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
    Dorfmeister B; Brandlhofer S; Schaap FG; Hermann M; Fürnsinn C; Hagerty BP; Stangl H; Patsch W; Strobl W
    Diabetologia; 2006 Jun; 49(6):1324-32. PubMed ID: 16570166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake.
    van den Berg SA; Heemskerk MM; Geerling JJ; van Klinken JB; Schaap FG; Bijland S; Berbée JF; van Harmelen VJ; Pronk AC; Schreurs M; Havekes LM; Rensen PC; van Dijk KW
    FASEB J; 2013 Aug; 27(8):3354-62. PubMed ID: 23650188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.
    Su X; Kong Y; Peng DQ
    Lipids Health Dis; 2018 Jul; 17(1):174. PubMed ID: 30053818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein A5 and hypertriglyceridemia in Prague hypertriglyceridemic rats.
    Kadlecová M; Hojná S; Bohuslavová R; Hubácek JA; Zicha J; Kunes J
    Physiol Res; 2006; 55(4):373-379. PubMed ID: 16238453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein A5, a unique modulator of fasting and postprandial triglycerides.
    May-Zhang L; Liu M; Black D; Tso P
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Sep; 1867(9):159185. PubMed ID: 35644522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects.
    Jang Y; Chae JS; Kim OY; Park HJ; Kim JY; Paik JK; Lee SH; Lee JH
    Atherosclerosis; 2010 Aug; 211(2):512-9. PubMed ID: 20392444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V.
    Bertoccini L; Sentinelli F; Incani M; Bailetti D; Cimini FA; Barchetta I; Cavallo MG; Cossu E; Lenzi A; Loche S; Baroni MG
    Lipids Health Dis; 2017 Sep; 16(1):179. PubMed ID: 28927406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen lowers triglyceride via regulating hepatic APOA5 expression.
    Luo F; Guo Y; Ruan GY; Peng R; Li XP
    Lipids Health Dis; 2017 Apr; 16(1):72. PubMed ID: 28376804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
    Jakel H; Nowak M; Helleboid-Chapman A; Fruchart-Najib J; Fruchart JC
    Ann Med; 2006; 38(1):2-10. PubMed ID: 16448983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia.
    Vaessen SF; Sierts JA; Kuivenhoven JA; Schaap FG
    Biochem Biophys Res Commun; 2009 Feb; 379(2):542-6. PubMed ID: 19121291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms.
    Treviño-Villarreal JH; Reynolds JS; Bartelt A; Langston PK; MacArthur MR; Arduini A; Tosti V; Veronese N; Bertozzi B; Brace LE; Mejia P; Trocha K; Kajitani GS; Longchamp A; Harputlugil E; Gathungu R; Bird SS; Bullock AD; Figenshau RS; Andriole GL; Thompson A; Heeren J; Ozaki CK; Kristal BS; Fontana L; Mitchell JR
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
    Forte TM; Ryan RO
    Curr Drug Targets; 2015; 16(12):1274-80. PubMed ID: 26028042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.